Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a grey zone combination of myelodysplastic and myeloproliferative features?

Sangiorgio VF, Geyer JT, Margolskee E, Al-Kawaaz M, Mathew S, Tam W, Orazi A.

Haematologica. 2019 Sep 26. pii: haematol.2019.227686. doi: 10.3324/haematol.2019.227686. [Epub ahead of print]

2.

Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with Increased blasts (<10%) or with other types of disease progression.

Geyer JT, Margolskee E, Krichevsky SA, Cattaneo D, Boiocchi L, Ronchi P, Lunghi F, Scandura JM, Ponzoni M, Hasserjian RP, Gianelli U, Iurlo A, Orazi A.

Haematologica. 2019 Sep 19. pii: haematol.2019.230193. doi: 10.3324/haematol.2019.230193. [Epub ahead of print]

3.

Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.

Liu YC, Margolskee E, Allan JN, Mathew S, Bhavsar E, Casano J, Orazi A, Furman RR, Geyer JT.

Mod Pathol. 2019 Sep 2. doi: 10.1038/s41379-019-0356-z. [Epub ahead of print]

PMID:
31477813
4.

A rare case of acute myeloid leukemia with der(1)t(1;19)(p13;p13.1).

McAlice M, Gohar M, Alshaban A, Orazi A, Tonk V, Chavali S, Tonk S, Gaur S.

Leuk Res Rep. 2019 Jun 8;12:100175. doi: 10.1016/j.lrr.2019.100175. eCollection 2019.

5.

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lübbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstöcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM.

Haematologica. 2019 Oct;104(10):1935-1949. doi: 10.3324/haematol.2019.222059. Epub 2019 May 2.

6.

Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group.

Weinberg OK, Hasserjian RP, Baraban E, Ok CY, Geyer JT, Philip JKSS, Kurzer JH, Rogers HJ, Nardi V, Stone RM, Garcia JS, Hsi ED, Bagg A, Wang SA, Orazi A, Arber DA.

Mod Pathol. 2019 Sep;32(9):1373-1385. doi: 10.1038/s41379-019-0263-3. Epub 2019 Apr 18.

PMID:
31000771
7.

Comments on pre-fibrotic myelofibrosis and how should it be managed.

Barbui T, Thiele J, Gisslinger H, Orazi A, Vannucchi AM, Gianelli U, Beham-Schmid C, Tefferi A.

Br J Haematol. 2019 Jul;186(2):358-360. doi: 10.1111/bjh.15840. Epub 2019 Mar 7. No abstract available.

PMID:
30847907
8.

Update on the pathologic diagnosis of chronic myelomonocytic leukemia.

Arber DA, Orazi A.

Mod Pathol. 2019 Jun;32(6):732-740. doi: 10.1038/s41379-019-0215-y. Epub 2019 Feb 5. Review.

PMID:
30723295
9.

Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.

Tang G, Sydney Sir Philip JK, Weinberg O, Tam W, Sadigh S, Lake JI, Margolskee EM, Rogers HJ, Miranda RN, Bueso-Ramos C C, Hsi ED, Orazi A, Hasserjian RP, Arber DA, Bagg A, Wang SA.

Mod Pathol. 2019 Apr;32(4):490-498. doi: 10.1038/s41379-018-0165-9. Epub 2018 Nov 6.

PMID:
30401948
10.

A multimodality work-up of patients with Hypereosinophilia.

Hu Z, Boddu PC, Loghavi S, Miranda RN, Goswami M, Medeiros LJ, Tam W, Orazi A, Verstovsek S, Wang SA.

Am J Hematol. 2018 Nov;93(11):1337-1346. doi: 10.1002/ajh.25247. Epub 2018 Sep 26.

11.

Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016.

Tzankov A, Kremer M, Leguit R, Orazi A, van der Walt J, Gianelli U, Hebeda KM.

Ann Hematol. 2018 Nov;97(11):2117-2128. doi: 10.1007/s00277-018-3436-0. Epub 2018 Aug 6.

12.

Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study.

Merzianu M, Groman A, Hutson A, Cotta C, Brynes RK, Orazi A, Reddy V, Teruya-Feldstein J, Amre R, Balasubramanian M, Brandao G, Cherian S, Courville E, Czuchlewski D, Fan G, Grier D, Hoehn D, Inamdar KV, Juskevicius R, Kaur P, Lazarchick J, Lewis MR, Miles RR, Myers JB, Nasr MR, Qureishi HN, Olteanu H, Robu VG, Salaru G, Vajpayee N, Vos J, Zhang L, Zhang S, Aye L, Brega E, Coad JE, Grantham J, Ivelja S, McKenna R, Sultan K, Wilding G, Hutchison R, Peterson L, Cheney RT.

Am J Clin Pathol. 2018 Oct 1;150(5):393-405. doi: 10.1093/ajcp/aqy066.

13.

Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.

Hebeda KM, Tzankov A, Boudova L, Saft L, Hasserjian RP, de Boer M, Fend F, Orazi A, Leguit R.

Pathobiology. 2019;86(1):62-75. doi: 10.1159/000489678. Epub 2018 Jul 6.

14.

Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms.

Kucine N, Al-Kawaaz M, Hajje D, Bussel J, Orazi A.

Br J Haematol. 2019 Apr;185(1):136-139. doi: 10.1111/bjh.15386. Epub 2018 May 16. No abstract available.

PMID:
29767848
15.

JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.

Aynardi J, Manur R, Hess PR, Chekol S, Morrissette JJD, Babushok D, Hexner E, Rogers HJ, Hsi ED, Margolskee E, Orazi A, Hasserjian R, Bagg A.

Br J Haematol. 2018 Jul;182(1):78-85. doi: 10.1111/bjh.15276. Epub 2018 May 16.

PMID:
29767839
16.

Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.

Wang X, Cao X, Sun R, Tang C, Tzankov A, Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, Tan X, Pang Y, Visco C, Xie Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Winter JN, Piris MA, Li S, Miranda RN, Medeiros LJ, Li Y, Xu-Monette ZY, Young KH.

Neoplasia. 2018 Jun;20(6):574-593. doi: 10.1016/j.neo.2018.03.002. Epub 2018 May 4.

17.

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A.

Blood Cancer J. 2018 Feb 9;8(2):15. doi: 10.1038/s41408-018-0054-y. Review.

18.

A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria.

Margolskee E, Mikita G, Rea B, Bagg A, Zuo Z, Sun Y, Goswami M, Wang SA, Oak J, Arber DA, Allen MB, George TI, Rogers HJ, Hsi E, Hasserjian RP, Orazi A.

Mod Pathol. 2018 Jun;31(6):873-880. doi: 10.1038/s41379-018-0001-2. Epub 2018 Feb 5.

19.

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Soderquist CR, Ewalt MD, Czuchlewski DR, Geyer JT, Rogers HJ, Hsi ED, Wang SA, Bueso-Ramos CE, Orazi A, Arber DA, Hexner EO, Babushok DV, Bagg A.

Mod Pathol. 2018 May;31(5):690-704. doi: 10.1038/modpathol.2017.182. Epub 2018 Jan 12.

20.

Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment.

Ghanima W, Boiocchi L, Lee CS, Feng X, Geyer JT, Gudbrandsdottir S, Orazi A, Junker P, Bussel JB.

Platelets. 2019;30(2):222-228. doi: 10.1080/09537104.2017.1411586. Epub 2018 Jan 2.

PMID:
29293383
21.

Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression.

Petrova-Drus K, Chiu A, Margolskee E, Barouk-Fox S, Geyer J, Dogan A, Orazi A.

Oncotarget. 2017 Oct 17;8(61):103274-103282. doi: 10.18632/oncotarget.21870. eCollection 2017 Nov 28.

22.

Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.

Chapman J, Geyer JT, Khanlari M, Moul A, Casas C, Connor ST, Fan YS, Watts JM, Swords RT, Vega F, Orazi A.

Mod Pathol. 2018 Mar;31(3):429-441. doi: 10.1038/modpathol.2017.148. Epub 2017 Dec 1.

23.

A lucky mistake: the splenic glands of Marcello Malpighi.

Pizzi M, Chaviano F, Rugge M, Orazi A.

Hum Pathol. 2018 Feb;72:191-195. doi: 10.1016/j.humpath.2017.11.007. Epub 2017 Nov 22.

PMID:
29175516
24.

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM.

Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.

25.

Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.

Margolskee E, Hasserjian RP, Hassane D, Tam W, Mathew S, Ok CY, Wang SA, Oak J, Arber DA, Orazi A.

Am J Clin Pathol. 2017 Jul 1;148(1):49-57. doi: 10.1093/ajcp/aqx043.

PMID:
28927162
26.

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.

Kvasnicka HM, Orazi A, Thiele J, Barosi G, Bueso-Ramos CE, Vannucchi AM, Hasserjian RP, Kiladjian JJ, Gianelli U, Silver R, Mughal TI, Barbui T.

Am J Hematol. 2017 Oct;92(10):1062-1067. doi: 10.1002/ajh.24837. Epub 2017 Jul 29.

27.

The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.

Gianelli U, Cattaneo D, Bossi A, Cortinovis I, Boiocchi L, Liu YC, Augello C, Bonometti A, Fiori S, Orofino N, Guidotti F, Orazi A, Iurlo A.

Mod Pathol. 2017 Jul;30(7):1043. doi: 10.1038/modpathol.2017.2.

28.

Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.

Geyer JT, Tam W, Liu YC, Chen Z, Wang SA, Bueso-Ramos C, Oak J, Arber DA, Hsi E, Rogers HJ, Levinson K, Bagg A, Hassane DC, Hasserjian RP, Orazi A.

Mod Pathol. 2017 Sep;30(9):1213-1222. doi: 10.1038/modpathol.2017.45. Epub 2017 May 26.

29.

The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.

Silver RT, Barel AC, Lascu E, Ritchie EK, Roboz GJ, Christos PJ, Orazi A, Hassane DC, Tam W, Cross NCP.

Cancer. 2017 Jul 15;123(14):2680-2687. doi: 10.1002/cncr.30679. Epub 2017 May 18.

30.

Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.

Wang SA, Hasserjian RP, Tam W, Tsai AG, Geyer JT, George TI, Foucar K, Rogers HJ, Hsi ED, Rea BA, Bagg A, Bueso-Ramos CE, Arber DA, Verstovsek S, Orazi A.

Haematologica. 2017 Aug;102(8):1352-1360. doi: 10.3324/haematol.2017.165340. Epub 2017 May 11.

31.

CD4-Negative Variant of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm With a Novel PBRM1 Mutation in an 11-Year-Old Girl.

Yigit N, Suarez LF, Roth LG, Orazi A, Tam W.

Am J Clin Pathol. 2017 May 1;147(5):453-460. doi: 10.1093/ajcp/aqx012. Erratum in: Am J Clin Pathol. 2017 Sep 1;148(3):280.

PMID:
28419186
32.

Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22): A Bone Marrow Pathology Group Multicenter Study.

Rogers HJ, Hsi ED, Tang G, Wang SA, Bueso-Ramos CE, Lubin D, Morrissette JJ, Bagg A, Cherukuri DP, George TI, Peterson L, Liu YC, Mathew S, Orazi A, Hasserjian RP.

Am J Clin Pathol. 2017 Apr 1;147(4):411-419. doi: 10.1093/ajcp/aqx020.

PMID:
28375434
33.
34.

Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version.

Iurlo A, Gianelli U, Cattaneo D, Thiele J, Orazi A.

Am J Hematol. 2017 Apr;92(4):E48-E51. doi: 10.1002/ajh.24657. Epub 2017 Feb 24. No abstract available.

35.

Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight cases.

Tsang HC, Bussel JB, Mathew S, Liu YC, Imahiyerobo AA, Orazi A, Geyer JT.

Mod Pathol. 2017 Apr;30(4):486-498. doi: 10.1038/modpathol.2016.218. Epub 2017 Jan 6.

36.

A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia.

Brynes RK, Wong RS, Thein MM, Bakshi KK, Burgess P, Theodore D, Orazi A.

Acta Haematol. 2017;137(2):66-72. doi: 10.1159/000452992. Epub 2016 Dec 23.

37.

RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.

Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, Wang J, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Pham LV, Young KH.

Aging (Albany NY). 2016 Dec 8;8(12):3321-3340. doi: 10.18632/aging.101121.

38.

Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients.

Margolskee E, Krichevsky S, Orazi A, Silver RT.

Haematologica. 2017 Mar;102(3):e97-e99. doi: 10.3324/haematol.2016.153973. Epub 2016 Nov 3. No abstract available.

39.

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH.

Blood. 2016 Dec 29;128(26):3083-3100. doi: 10.1182/blood-2016-05-715094. Epub 2016 Oct 19.

40.

The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.

Gianelli U, Cattaneo D, Bossi A, Cortinovis I, Boiocchi L, Liu YC, Augello C, Bonometti A, Fiori S, Orofino N, Guidotti F, Orazi A, Iurlo A.

Mod Pathol. 2017 Feb;30(2):169-179. doi: 10.1038/modpathol.2016.182. Epub 2016 Oct 14. Erratum in: Mod Pathol. 2017 Jul;30(7):1043.

41.

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.

Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li Y, Li J, Medeiros LJ, Young KH.

Leukemia. 2017 Mar;31(3):625-636. doi: 10.1038/leu.2016.243. Epub 2016 Aug 29.

42.

The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis.

Pizzi M, Gergis U, Chaviano F, Orazi A.

Hematol Oncol Stem Cell Ther. 2016 Sep;9(3):96-104. doi: 10.1016/j.hemonc.2016.07.002. Epub 2016 Aug 6.

43.

Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome.

Petrova-Drus K, Hasserjian R, Pozdnyakova O, Dal Cin P, Mathew S, Margolskee E, Orazi A, Geyer JT.

Leuk Lymphoma. 2017 Mar;58(3):569-577. doi: 10.1080/10428194.2016.1203432. Epub 2016 Jul 7.

PMID:
27389864
44.
45.

Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.

Wang SA, Tam W, Tsai AG, Arber DA, Hasserjian RP, Geyer JT, George TI, Czuchlewski DR, Foucar K, Rogers HJ, Hsi ED, Bryan Rea B, Bagg A, Dal Cin P, Zhao C, Kelley TW, Verstovsek S, Bueso-Ramos C, Orazi A.

Mod Pathol. 2016 Aug;29(8):854-64. doi: 10.1038/modpathol.2016.75. Epub 2016 May 13.

46.

Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates.

Geyer JT, Orazi A.

Int J Lab Hematol. 2016 May;38 Suppl 1:12-9. doi: 10.1111/ijlh.12509. Epub 2016 May 9. Review.

PMID:
27161873
47.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW.

Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11. Review.

PMID:
27069254
48.

Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.

Xu-Monette ZY, Deng Q, Manyam GC, Tzankov A, Li L, Xia Y, Wang XX, Zou D, Visco C, Dybkær K, Li J, Zhang L, Liang H, Montes-Moreno S, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Wang SA, Miranda RN, Piris MA, Winter JN, Medeiros LJ, Li Y, Young KH.

Clin Cancer Res. 2016 Jul 15;22(14):3593-605. doi: 10.1158/1078-0432.CCR-15-2296. Epub 2016 Feb 29.

49.

Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.

Shanmugam V, Margolskee E, Kluk M, Giorgadze T, Orazi A.

Head Neck Pathol. 2016 Sep;10(3):394-9. doi: 10.1007/s12105-016-0709-6. Epub 2016 Feb 27.

50.

p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.

Xu-Monette ZY, Zhang S, Li X, Manyam GC, Wang XX, Xia Y, Visco C, Tzankov A, Zhang L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Young KH.

Aging (Albany NY). 2016 Feb;8(2):345-65.

Supplemental Content

Support Center